BRINGING QUALITY, EXPERTISE AND TRUST TO CANNABIS
We put patients and people first. By providing a portfolio of high-quality
cannabis-based health and wellness solutions, leveraging data and research to
fuel innovation, and improving access to cannabis and plant-based solutions, we
aim to lead the industry.
Columbia Care Inc. is one of the largest and most experienced multi-state operators in
the medical cannabis industry, with licenses in 15 jurisdictions in the US and
the EU. With over 1,000,000 successful sales transactions since its inception, Columbia Care
is a patient-centered organization setting the standard for compassion,
professionalism, quality, caring and innovation, working in collaboration with
some of the most renowned and innovative teaching hospitals and medical centers
in the world. The Company is committed to providing the type of education and
transparency patients deserve and quality of product that clinicians expect.
With six-plus years of strong organic growth, disciplined operationalization of
licenses, over 1 million sales transactions since inception, and having built
14 state-by-state vertically integrated operations, including 54 facilities in
operation or development, and 35 licenses in 15 markets, we understand
regulators, compliance, cultivation, manufacturing, quality control,
physicians, caregivers, dispensaries, patients, and data inherent for success
in this industry. In addition to our medical cannabis products, we also offer a variety of health
and wellness brands and products, including our own hemp CBD brands that are
full spectrum, independent 3rd party tested, organic, GMO-free, and produced in
cGMP-compliant facilities. Our flagship hemp CBD brand, Columbia Care Platinum
Label, aims to set the standard in potency and purity.
COLUMBIA CARE LAUNCHES “100,000,000 WAYS TO BREAK THE OPIOID CRISIS”
INITIATIVE
Columbia Care to partner with experts at Montefiore Medical Center and Albert Einstein
College of Medicine for initial phase of nationwide study on medical cannabis’s
impact on opioid use for pain.
Columbia Care is kicking off the “100,000,000 Ways to Break the Opioid Crisis”
initiative by providing its precisely-formulated pharmaceutical-quality
cannabis-based medicines for a precedent-setting study to determine whether
medical cannabis can reduce participants’ dependence on opioid use in managing
pain. This study, which is being conducted at Montefiore Medical Center and
Albert Einstein College of Medicine in the Bronx, will add to the body of
knowledge to inform healthcare practices and public policies in this arena. The
study is expected to be expanded to other hospitals throughout New York State
and, ultimately, to other states where Columbia Care’s formulated medical
cannabis products are also available.
Renowned addiction experts Dr. Chinazo Cunningham and Dr. Julia Arnsten, who are both
researchers at Montefiore and Einstein, are leading the study.
DISCOVER HOW COLUMBIA CARE ARE DEVELOPING PRODUCTS TO MEET AN UNMET CLINICAL NEED IN WOMEN SUFFERING FROM PELVIC CONDITIONS.
